Precision Health Clinical Trials

Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

Condition:   Triple Negative Breast Cancers Without Lymph-node Involvement and Intervention:   Procedure: Blood samples of 10 mL
Sponsor:   Institut Claudius Regaud

Cerebellar Mutism Syndrome Study

Conditions:   Infratentorial Neoplasms;   Mutism
Sponsors:   Rigshospitalet, Denmark;   Odense University Hospital;   Aarhus University Hospital;   Aalborg University Hospital;   Technical University of Denmark;   Karolinska University Hospital;   Skane University Hospital;   University Hospital, Linkoeping;   Uppsala University Hospital;   Sahlgrenska University Hospital, Sweden;   University Hospital, Umeå;   Oslo University Hospital;   Trondheim University Hospital;   Haukeland University Hospital;   University Hospital of North Norway;   Helsinki University Central Hospital;   Tampere University Hospital;   Kuopio University Hospital;   Turku University Hospital;   Oulu University Hospital;   Radboud University Medical Center;   Liverpool University Hospitals NHS Foundation Trust;   Great Ormond Street Hospital for Children NHS Foundation Trust;   Nottingham University Hospitals NHS Trust;   University Hospital Birmingham;   University Hospitals Bristol and Weston NHS Foundation Trust;   Royal Infirmary of Edinburgh;   South Glasgow University Hospitals NHS Trust;   University Hospital Tuebingen;   Medical University of Vienna;   Ospedale Pediatrico Bambin Gesù

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Condition:   Malignant Neoplasm
Interventions:   Drug: ponatinib hydrochloride;   Other: laboratory biomarker analysis
Sponsor:   Sameek Roychowdhury

Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases

Condition:   Retinitis Pigmentosa
Intervention:   Genetic: Genetic testing
Sponsors:   Hillel Yaffe Medical Center;   Technion, Israel Institute of Technology
Not yet recruiting

Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections

Conditions:   Laboratory-confirmed Bloodstream Infection;   Central Line-associated Bloodstream Infections;   Mucosal Barrier Injury
Sponsor:   Boston Children's Hospital

Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer

Conditions:   Non-small Cell Lung Cancer;   Small Cell Lung Cancer
Interventions:   Other: cytology specimen collection procedure;   Other: laboratory biomarker analysis
Sponsors:   University of Southern California;   Foundation Medicine;   Addario Lung Cancer Medical Institute;   National Cancer Institute (NCI)

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: AZD2014;   Drug: AZD4547;   Drug: AZD5363;   Drug: AZD8931;   Drug: Selumetinib;   Drug: Vandetanib;   Drug: Bicalutamide;   Drug: Olaparib;   Drug: Anthracyclines;   Drug: Taxanes;   Drug: cyclophosphamide;   Drug: DNA intercalators;   Drug: Methotrexate;   Drug: vinca alkaloids;   Drug: Platinum based chemotherapies;   Drug: Bevacizumab;   Drug: Mitomycin C;   Drug: Eribulin;   Drug: MEDI4736
Sponsors:   UNICANCER;   Fondation ARC;   AstraZeneca

Detection of Tumor DNA in Blood Samples From Cancer Patients

Conditions:   Cancer;   Tumors
Intervention:   Diagnostic Test: Blood test
Sponsor:   Lexent Bio, Inc.

Genomic Response Analysis of Heart Failure Therapy in African Americans

Condition:   Heart Failure
Intervention:   Drug: FDC I/H
Sponsor:   University of Pittsburgh

Genes Involved in Lipid Disorders

Condition:   Lipid Disorders
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)